Morken, Siren http://orcid.org/0009-0003-8676-772X
Langer, Seppo W.
Sundlöv, Anna
Vestermark, Lene Weber
Ladekarl, Morten http://orcid.org/0000-0002-0182-1228
Hjortland, Geir Olav
Svensson, Johanna B.
Tabaksblat, Elizaveta Mitkina
Haslerud, Torjan Magne
Assmus, Jörg
Detlefsen, Sönke
Couvelard, Anne
Perren, Aurel
Sorbye, Halfdan
Article History
Received: 19 June 2023
Revised: 22 September 2023
Accepted: 4 October 2023
First Online: 23 October 2023
Competing interests
: HS: Consultant/advisory board: Hutchison, Bayer, ITM, AAA. Lecture Honoraria; Novartis, Ipsen, Bayer, SAM Nordic, Pierre Fabre. ML: Unrestricted research grant from Scandion Oncology A/S.
: The protocol was approved by the National Competent Authorities in the participating countries (Sweden, Norway and Denmark) and registered in ClinicalTrials.gov (NTC02248012). The study was conducted in accordance with the Declaration of Helsinki and ICH guidelines for Good Clinical Practice. Written informed consent was obtained from all patients prior to inclusion.
: Not relevant.